NCT00986479View on ClinicalTrials.gov

This is a Study to Determine the Antidepressant Effects of AZD6765

PHASE2CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Treatment Resistant Major Depressive Disorder

Interventions

DRUG

AZD6765

Single IV infusion of 150 mg AZD6765.

DRUG

Placebo to AZD6765

Single IV infusion of Placebo to AZD6765

Trial Locations (1)

Unknown

Research Site, Bethesda

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

AstraZeneca

INDUSTRY